These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

76 related items for PubMed ID: 8961776

  • 1. A double-blind trial of low- and high-dose ranges of gepirone-ER compared with placebo in the treatment of depressed outpatients.
    Wilcox CS, Ferguson JM, Dale JL, Heiser JF.
    Psychopharmacol Bull; 1996; 32(3):335-42. PubMed ID: 8961776
    [Abstract] [Full Text] [Related]

  • 2. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
    Alpert JE, Franznick DA, Hollander SB, Fava M.
    J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
    [Abstract] [Full Text] [Related]

  • 3. Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder.
    Feiger AD, Heiser JF, Shrivastava RK, Weiss KJ, Smith WT, Sitsen JM, Gibertini M.
    J Clin Psychiatry; 2003 Mar; 64(3):243-9. PubMed ID: 12716264
    [Abstract] [Full Text] [Related]

  • 4. Sustained efficacy of gepirone-IR in major depressive disorder: a double-blind placebo substitution trial.
    Amsterdam JD, Brunswick DJ, Gibertini M.
    J Psychiatr Res; 2004 Mar; 38(3):259-65. PubMed ID: 15003431
    [Abstract] [Full Text] [Related]

  • 5. A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression.
    Feiger AD.
    Psychopharmacol Bull; 1996 Mar; 32(4):659-65. PubMed ID: 8993088
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 7. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM, Mallinckrodt CH, Prakash A, Watkin JG, Carter WP.
    Depress Anxiety; 2007 Feb; 24(1):41-52. PubMed ID: 16845641
    [Abstract] [Full Text] [Related]

  • 8. Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel-group study.
    Bielski RJ, Cunningham L, Horrigan JP, Londborg PD, Smith WT, Weiss K.
    J Clin Psychiatry; 2008 Apr; 69(4):571-7. PubMed ID: 18373383
    [Abstract] [Full Text] [Related]

  • 9. Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia.
    Mendels J, Kiev A, Fabre LF.
    Depress Anxiety; 1999 Apr; 9(2):54-60. PubMed ID: 10207659
    [Abstract] [Full Text] [Related]

  • 10. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
    Patkar AA, Masand PS, Pae CU, Peindl K, Hooper-Wood C, Mannelli P, Ciccone P.
    J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
    [Abstract] [Full Text] [Related]

  • 11. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
    Davidson JR, Meoni P, Haudiquet V, Cantillon M, Hackett D.
    Depress Anxiety; 2002 Dec; 16(1):4-13. PubMed ID: 12203668
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study.
    Mendels J, Johnston R, Mattes J, Riesenberg R.
    Psychopharmacol Bull; 1993 Dec; 29(2):169-74. PubMed ID: 8290661
    [Abstract] [Full Text] [Related]

  • 13. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
    Kivitz A, Ma C, Ahdieh H, Galer BS.
    Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
    [Abstract] [Full Text] [Related]

  • 14. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.
    Septien-Velez L, Pitrosky B, Padmanabhan SK, Germain JM, Tourian KA.
    Int Clin Psychopharmacol; 2007 Nov; 22(6):338-47. PubMed ID: 17917552
    [Abstract] [Full Text] [Related]

  • 15. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder.
    Munizza C, Olivieri L, Di Loreto G, Dionisio P.
    Curr Med Res Opin; 2006 Sep; 22(9):1703-13. PubMed ID: 16968574
    [Abstract] [Full Text] [Related]

  • 16. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [Abstract] [Full Text] [Related]

  • 17. Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials.
    Khan A, Brodhead AE, Kolts RL, Brown WA.
    J Psychiatr Res; 2005 Mar; 39(2):145-50. PubMed ID: 15589562
    [Abstract] [Full Text] [Related]

  • 18. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care.
    Wade A, Crawford GM, Angus M, Wilson R, Hamilton L.
    Int Clin Psychopharmacol; 2003 May; 18(3):133-41. PubMed ID: 12702891
    [Abstract] [Full Text] [Related]

  • 19. Relapse prevention with gepirone ER in outpatients with major depression.
    Keller MB, Ruwe FJ, Janssens CJ, Sitsen JM, Jokinen R, Janczewski J.
    J Clin Psychopharmacol; 2005 Feb; 25(1):79-84. PubMed ID: 15643103
    [Abstract] [Full Text] [Related]

  • 20. Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers.
    Canuso CM, Schooler N, Carothers J, Turkoz I, Kosik-Gonzalez C, Bossie CA, Walling D, Lindenmayer JP.
    J Clin Psychopharmacol; 2010 Oct; 30(5):487-95. PubMed ID: 20814330
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.